Dr. Mustafa M. Rawaf, DO

Medicare patients and services

Medicare patients, 2024

182

Services billed

530

Patients’ average age

63

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 40 payments worth $41,118 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Nevada →

Industry-funded research

Named as a principal investigator on 17 industry-funded studies in 2025, from 9 companies. The companies reported $1,109,476 in research payments for these studies, mostly to the institutions running them.

• A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
  Axsome Therapeutics, Inc.
• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
  E.r. Squibb & Sons, L.l.c.
• BXCL501401
  Bioxcel Therapeutics, Inc.
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
  E.r. Squibb & Sons, L.l.c.
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
  AbbVie Inc. · Terminated · NCT05443724
• Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
  Indivior Inc. · Completed · NCT06384157
• A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia
  Boehringer Ingelheim International GmbH
• Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder
  AbbVie Inc.
• Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
  AbbVie Inc. · Recruiting · NCT06846320
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
  E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Psychiatry clinicians in Las Vegas

• Adekunle Ajayi, M.D.
• Steve Alcazar, MD
• Tarik Alshaikh, D.O.
• John V. Anooshian, MD
• Daphne Antillon, DO
• Valerie C. Archer, APRN, PMHNP
• Sahar Azim
• Saleha K. Baig, MD